Francis Ayuk

11.4k total citations · 1 hit paper
164 papers, 3.9k citations indexed

About

Francis Ayuk is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Francis Ayuk has authored 164 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Hematology, 50 papers in Oncology and 45 papers in Genetics. Recurrent topics in Francis Ayuk's work include Hematopoietic Stem Cell Transplantation (81 papers), Acute Myeloid Leukemia Research (40 papers) and Multiple Myeloma Research and Treatments (35 papers). Francis Ayuk is often cited by papers focused on Hematopoietic Stem Cell Transplantation (81 papers), Acute Myeloid Leukemia Research (40 papers) and Multiple Myeloma Research and Treatments (35 papers). Francis Ayuk collaborates with scholars based in Germany, United States and Italy. Francis Ayuk's co-authors include Nicolaus Kröger, Tatjana Zabelina, Christine Wolschke, Axel R. Zander, Boris Fehse, Ulrike Bacher, Anita Badbaran, Helmut Renges, Nico Gagelmann and Maximilian Christopeit and has published in prestigious journals such as Nature Communications, Blood and Cancer.

In The Last Decade

Francis Ayuk

153 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis

2024 78 citations Johanna Richter, Boris Fehse et al. Med profile →

Peers

Countries citing papers authored by Francis Ayuk

Since Specialization

Citations

This map shows the geographic impact of Francis Ayuk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francis Ayuk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francis Ayuk more than expected).

Fields of papers citing papers by Francis Ayuk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francis Ayuk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francis Ayuk. The network helps show where Francis Ayuk may publish in the future.

Co-authorship network of co-authors of Francis Ayuk

This figure shows the co-authorship network connecting the top 25 collaborators of Francis Ayuk. A scholar is included among the top collaborators of Francis Ayuk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francis Ayuk. Francis Ayuk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis 2025 ·Bone Marrow Transplantation ·(unknown), (unknown), Jörg Halter, (unknown), Friedrich Stölzel, Markus Perl, (unknown), Matthias Edinger, Wolfgang Herr, Nicolaus Kröger, Daniel Wolff, Francis Ayuk, Matthias Fante	6
2	A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy—case report and literature review 2025 ·Lara D. Veeken ·Isabell Haase, (unknown), (unknown), Boris Fehse, Nikolas Ruffer, (unknown), (unknown), Nico Gagelmann, Dominic Borie, Francis Ayuk, Ina Kötter, Martin Krusche, Nicolaus Kröger	1
3	Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post‐Transplant Cyclophosphamide in MRD‐Negative but Not in MRD‐Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Complete Remission 2024 ·European Journal Of Haematology ·Normann Steiner, Radwan Massoud, Johanna Richter, (unknown), Nico Gagelmann, Christian Niederwieser, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Christine Wolschke, Francis Ayuk, Evgeny Klyuchnikov, Nicolaus Kröger	0
4	CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis breakdown → 2024 ·Med ·(unknown), Johanna Richter, (unknown), Boris Fehse, (unknown), Stefanie Reinhardt, Jens Kühle, Anita Badbaran, (unknown), Nico Gagelmann, Dominic Borie, (unknown), Francis Ayuk, Manuel A. Friese, Christoph Heesen, Nicolaus Kröger	78
5	CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture 2024 ·Cancers ·(unknown), (unknown), Dawid Głów, Maximilian Jung, (unknown), Nicolaus Kröger, Stefan Horn, Kristoffer Riecken, Boris Fehse, Francis Ayuk	6
6	Dose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML) 2024 ·Cancers ·(unknown), (unknown), (unknown), Michael Heuser, Felicitas Thol, Francis Ayuk, Christine Wolschke, Evgeny Klyuchnikov, Carsten Bokemeyer, Walter Fiedler, (unknown)	0
7	Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment 2023 ·Frontiers in Oncology ·(unknown), Claudia Langebrake, (unknown), (unknown), (unknown), Nicolaus Kröger, Francis Ayuk	4
8	Data-driven grading of acute graft-versus-host disease 2023 ·Nature Communications ·(unknown), (unknown), Francis Ayuk, Gernot Beutel, Olaf Penack, Thomas Luft, (unknown), Gastone Castellani, Hans Christian Reinhardt, Nicolaus Kröger, Dietrich W. Beelen, Amin T. Turki	3
9	Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis 2023 ·Transplantation and Cellular Therapy ·(unknown), Wolfgang Bethge, (unknown), (unknown), Bastian von Tresckow, Francis Ayuk, Olaf Penack, Vladan Vučinić, Malte von Bonin, Claudia D. Baldus, Dimitrios Mougiakakos, Gerald Wulf, Ulf Schnetzke, Matthias Stelljes, Matthias Fante, Roland Schroers, Nicolaus Kroeger, Peter Dreger	8
10	Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study 2023 ·Blood Advances ·Maria‐Luisa Schubert, Wolfgang Bethge, Francis Ayuk, Malte von Bonin, Vladan Vučinić, Eva Wagner-Drouet, Marion Subklewe, Claudia D. Baldus, Bertram Glaß, Reinhard Marks, Dimitrios Mougiakakos, Roland Schroers, Matthias Stelljes, Max S. Topp, Gerald Wulf, Nicolaus Kröger, Peter Dreger	9
11	Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission 2022 ·Transplantation and Cellular Therapy ·Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, (unknown), (unknown), Francis Ayuk, Christine Wolschke, Ulrike Bacher, Nicolaus Kröger	7
12	Post-Transplantation Multicolored Flow Cytometry–Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia 2022 ·Transplantation and Cellular Therapy ·Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, (unknown), (unknown), Francis Ayuk, Maximilian Christopeit, Christine Wolschke, Ulrike Bacher, Nicolaus Kröger	5
13	Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients 2022 ·International Journal of Oncology ·Maria‐Luisa Schubert, Carolina Berger, Alexander Kunz, Anita Schmitt, Anita Badbaran, Brigitte Neuber, (unknown), Lei Wang, Kristoffer Riecken, Angela Hückelhoven‐Krauss, Ingo Müller, Carsten Müller‐Tidow, Peter Dreger, Nicolaus Kröger, Francis Ayuk, Michael Schmitt, Boris Fehse	9
14	Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy 2022 ·Haematologica ·(unknown), Boris Fehse, Nuray Akyüz, Maria Geffken, Christine Wolschke, (unknown), Nico Gagelmann, (unknown), Dominic Wichmann, Christian Frenzel, (unknown), Anna Alegiani, Anita Badbaran, (unknown), Judith Dierlamm, Nicolaus Kröger, Francis Ayuk	14
15	Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML 2021 ·Bone Marrow Transplantation ·Christian Niederwieser, Еlena V. Morozova, L. S. Zubarovskaya, Tatjana Zabelina, Evgeny Klyuchnikov, (unknown), Christine Wolschke, Maximilian Christopeit, Francis Ayuk, Ivan Moiseev, Boris V. Afanasyev, Nicolaus Kröger	12
16	Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT) 2021 ·Blood ·Stephanie J. Lee, Franco Locatelli, Francis Ayuk, Tsila Zuckerman, Kentaro Fukushima, (unknown), Joseph Pidala, Nada Hamad, Ivan Moiseev, Francesca Bonifazi, Shashikant Apte, Robert Zeiser, Valkal Bhatt, (unknown), Jackie Han, Tommaso Stefanelli, Mike W. Zuurman, Takanori Teshima	1
17	The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study 2019 ·Journal of Hepatology ·Johann von Felden, Laurent Alric, Sven Pischke, Celia Aitken, Stefan Schlabe, Ulrich Spengler, Maria Teresa Giordani, Paul Schnitzler, Dominik Bettinger, Robert Thimme, Aliénor Xhaard, Mascha Binder, Francis Ayuk, Ansgar W. Lohse, Jan J. Cornelissen, Robert A. de Man, Vincent Mallet	62
18	Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines. 2014 ·PubMed ·(unknown), (unknown), I. Brammer, Andrea Pace, Gunter Schuch, Carsten Bokemeyer, Axel R. Zander, Nicolaus Kröger, Francis Ayuk	2
19	CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies 2013 ·Biology of Blood and Marrow Transplantation ·Evgeny Klyuchnikov, Jean El Cheikh, Andreas Sputtek, Michael Lioznov, Boris Calmels, Sabine Fürst, Christian Chabannon, Roberto Crocchiolo, Claude Lemarié, Catherine Faucher, Ulrike Bacher, Haefaa Alchalby, Thomas Stübig, Christine Wolschke, Francis Ayuk, (unknown), Didier Blaise, Nicolaus Kröger	67
20	Risk models predicting survival after reduced‐intensity transplantation for myelofibrosis 2012 ·British Journal of Haematology ·Haefaa Alchalby, (unknown), Tatjana Zabelina, Guido Kobbe, Ernst Holler, Martin Bornhäuser, Rainer Schwerdtfeger, Wolfgang Bethge, Hans Michael Kvasnicka, Guntram Büsche, Francis Ayuk, Ulrike Bacher, Axel R. Zander, Nicolaus Kröger	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact